Clinical Trial Update: Tarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS) [Phase 2]

View source ↗

Summary

TAURUS is a Phase 2 clinical trial evaluating tarlatamab for advanced extrapulmonary small cell carcinoma and neuroendocrine carcinoma, with current status not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extrapulmonary Small Cell Carcinoma
• Neuroendocrine Carcinoma

Drugs mentioned

• Tarlatamab

Snippet

Sponsor: National Taiwan University Hospital | Conditions: Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING